Validity and Reliability of the Japanese Version of the Rome III Diagnostic Questionnaire for Irritable Bowel Syndrome and Functional Dyspepsia

Overview

Journal J Neurogastroenterol Motil

Date 2015 Sep 10

PMID 26350938

Citations 17

Authors

Motoyori Kanazawa

Shigemi Nakajima

Tadayuki Oshima

William E Whitehead

Ami D Sperber

Olafur S Palsson

Douglas A Drossman

Hiroto Miwa

Shin Fukudo

Affiliations

Soon will be listed here.

Abstract

Background/aims: Reliable diagnostic instruments for measuring the presence of functional gastrointestinal disorders based on the Rome III criteria have been lacking in Japan. The aims of the present study were to translate and validate the Rome III diagnostic questionnaire which was widely used in Western countries.

Methods: The original version of Rome III diagnostic questionnaire was translated from English into Japanese through 3 independent forward translations, resolution, back translation and reconciliation of the differences. Forty-nine patients with irritable bowel syndrome (IBS), 32 patients with functional dyspepsia (FD) and 56 subjects without any current GI symptoms as controls were recruited from three hospitals located in different regions of Japan and completed the IBS and FD diagnostic modules twice within 14 days. Kappa statistic was used to assess test-retest reliability. The sensitivity and specificity of each diagnostic module for distinguishing IBS or FD patients from controls was tested.

Results: Median kappa statistics were 0.63 for the translated IBS diagnostic module and 0.68 for the FD module. The sensitivity, specificity, and positive predict value of the IBS module against physician diagnosis was 61.2%, 100%, and 100% and those of the FD module was 53.2%, 98.2%, and 94.4%, respectively. Meanwhile, IBS patients were significantly more likely to report blood in stools compared to controls (18.4% vs 1.8%, P < 0.01).

Conclusions: The IBS and FD diagnostic modules on the Japanese version of the Rome III diagnostic questionnaire are valid and reliable. Further studies are warranted to elucidate the diagnostic utility of the red flag questionnaire.

Citing Articles

Factors Associated With the Prevalence of Irritable Bowel Syndrome: The Miyagi Part of the Tohoku Medical Megabank Project Community-based Cohort Study.

Nakaya K, Nakaya N, Kogure M, Hatanaka R, Chiba I, Kanno I J Neurogastroenterol Motil. 2024; 30(2):208-219.

PMID: 38576370 PMC: 10999836. DOI: 10.5056/jnm23090.

Impact of weight loss for depressive symptom in mid-stage patients with Parkinson's disease: a 4-year follow-up study.

Kurihara K, Fujioka S, Mishima T, Tsuboi Y Front Neurol. 2024; 14:1306138.

PMID: 38249744 PMC: 10796778. DOI: 10.3389/fneur.2023.1306138.

Effect of G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn's Disease: A Prospective Pilot Study.

Tomita T, Fukui H, Okugawa T, Nakanishi T, Mieno M, Nakai K J Clin Med. 2023; 12(10).

PMID: 37240476 PMC: 10219535. DOI: 10.3390/jcm12103368.

Prevalence of Irritable Bowel Syndrome in Japan, China, and South Korea: An International Cross-sectional Study.

Takeoka A, Kimura T, Hara S, Hamaguchi T, Fukudo S, Tayama J J Neurogastroenterol Motil. 2023; 29(2):229-237.

PMID: 37019867 PMC: 10083109. DOI: 10.5056/jnm22037.

Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.

Tomita T, Fukui H, Morishita D, Mori S, Oshima T, Shinzaki S J Clin Med. 2022; 11(23).

PMID: 36498457 PMC: 9736938. DOI: 10.3390/jcm11236882.

References

Spiegel B, Bolus R, Harris L, Lucak S, Naliboff B, Esrailian E . Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther. 2009; 30(11-12):1159-70. PMC: 2793273. DOI: 10.1111/j.1365-2036.2009.04144.x. View

Ghoshal U, Gwee K, Chen M, Gong X, Pratap N, Hou X . Development, Translation and Validation of Enhanced Asian Rome III Questionnaires for Diagnosis of Functional Bowel Diseases in Major Asian Languages: A Rome Foundation-Asian Neurogastroenterology and Motility Association Working Team Report. J Neurogastroenterol Motil. 2014; 21(1):83-92. PMC: 4288097. DOI: 10.5056/jnm14045. View

Shinozaki M, Kanazawa M, Sagami Y, Endo Y, Hongo M, Drossman D . Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index. J Gastroenterol. 2006; 41(5):491-4. DOI: 10.1007/s00535-006-1799-9. View

Whitehead W, Drossman D . Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review. Am J Gastroenterol. 2010; 105(4):814-20. PMC: 3856202. DOI: 10.1038/ajg.2010.56. View

Saigo T, Tayama J, Hamaguchi T, Nakaya N, Tomiie T, Bernick P . Gastrointestinal specific anxiety in irritable bowel syndrome: validation of the Japanese version of the visceral sensitivity index for university students. Biopsychosoc Med. 2014; 8(1):10. PMC: 3994456. DOI: 10.1186/1751-0759-8-10. View

Hammer J, Eslick G, Howell S, Altiparmak E, Talley N . Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut. 2004; 53(5):666-72. PMC: 1774043. DOI: 10.1136/gut.2003.021857. View

Francis C, Morris J, Whorwell P . The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997; 11(2):395-402. DOI: 10.1046/j.1365-2036.1997.142318000.x. View

Von Reisswitz P, Mazzoleni L, Sander G, Francisconi C . Portuguese validation of the Rome III diagnostic questionnaire for functional dyspepsia. Arq Gastroenterol. 2011; 47(4):354-60. DOI: 10.1590/s0004-28032010000400007. View

Nakajima S, Takahashi K, Sato J, Fukuda M, Yamamoto K, Inoue T . Spectra of functional gastrointestinal disorders diagnosed by Rome III integrative questionnaire in a Japanese outpatient office and the impact of overlapping. J Gastroenterol Hepatol. 2010; 25 Suppl 1:S138-43. DOI: 10.1111/j.1440-1746.2010.06244.x. View

10.

Nishino Y, Suzuki Y, Ohmori K, Hozawa A, Ogawa K, Kuriyama S . Cancer incidence profiles in the Miyagi Cohort Study. J Epidemiol. 2004; 14 Suppl 1:S7-11. PMC: 8828276. DOI: 10.2188/jea.14.s7. View

11.

Chang L, Toner B, Fukudo S, Guthrie E, Locke G, Norton N . Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology. 2006; 130(5):1435-46. DOI: 10.1053/j.gastro.2005.09.071. View

12.

Whitehead W, Palsson O, Feld A, Levy R, von Korff M, Turner M . Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. Aliment Pharmacol Ther. 2006; 24(1):137-46. DOI: 10.1111/j.1365-2036.2006.02956.x. View

13.

Lee Y, Waid A, Tan H, Chua S, Whitehead W . Validity and reliability of the Malay-language translation of the Rome III Diagnostic Questionnaire for irritable bowel syndrome. J Gastroenterol Hepatol. 2011; 27(4):746-50. DOI: 10.1111/j.1440-1746.2011.06943.x. View

14.

Miwa H . Life style in persons with functional gastrointestinal disorders--large-scale internet survey of lifestyle in Japan. Neurogastroenterol Motil. 2012; 24(5):464-71, e217. DOI: 10.1111/j.1365-2982.2011.01872.x. View

15.

Song K, Jung H, Min B, Youn Y, Choi K, Keum B . Development and Validation of the Korean Rome III Questionnaire for Diagnosis of Functional Gastrointestinal Disorders. J Neurogastroenterol Motil. 2013; 19(4):509-15. PMC: 3816186. DOI: 10.5056/jnm.2013.19.4.509. View

16.

Sperber A . Translation and validation of study instruments for cross-cultural research. Gastroenterology. 2004; 126(1 Suppl 1):S124-8. DOI: 10.1053/j.gastro.2003.10.016. View

17.

Heaton K, Radvan J, Cripps H, Mountford R, Braddon F, Hughes A . Defecation frequency and timing, and stool form in the general population: a prospective study. Gut. 1992; 33(6):818-24. PMC: 1379343. DOI: 10.1136/gut.33.6.818. View

18.

Vandvik P, Aabakken L, Farup P . Diagnosing irritable bowel syndrome: poor agreement between general practitioners and the Rome II criteria. Scand J Gastroenterol. 2004; 39(5):448-53. DOI: 10.1080/00365520310008782. View